date name shares transaction value  thomas l wegman president director    disposition at  per share   thomas l wegman president director    disposition at  per share   estate of edwin h wegman director    disposition at  per share   estate of edwin h wegman director    disposition at  per share   thomas l wegman president director    disposition at  per share   thomas l wegman president director    disposition at  per share   estate of edwin h wegman director    disposition at  per share   estate of edwin h wegman director    disposition at  per share   estate of edwin h wegman director    disposition at  per share   estate of edwin h wegman director    disposition at  per share   estate of edwin h wegman director    disposition at  per share   estate of edwin h wegman director    disposition at  per share   estate of edwin h wegman director    disposition at  per share   estate of edwin h wegman director    disposition at  per share   estate of edwin h wegman director    disposition at  per share   thomas l wegman president director    derivativenonderivative trans at  per share   thomas l wegman president director    derivativenonderivative trans at  per share   estate of edwin h wegman director    disposition at  per share   thomas l wegman president director    disposition at  per share  newslatestcompanyusbstc marketwatch news on bstc sarbox contd more reasons to stay tough  pm april    herb greenberg biospecifics to be delisted from nasdaq smallcap wed  pm march    carolyn pritchard biospecifics gets nasdaq delisting notice  pm nov    jenny spitz sun inktomi neurocrine and more  pm dec    michael baron updates advisories and surprises  pm dec    cbsmarketwatchcom biospecifics looks for additional funding  pm dec    michael baron newsnonmarketwatchcompanyusbstc other news on bstc biospecifics technologies bstc presents at jefferies  global healthcare conference  am june    seeking alpha can this biotech stock with  eps growth launch new breakout  am june    investors business daily pharma stock with tripledigit growth forming blotchy base  am may    investors business daily biotech breakout ahead incyte rising on success with merk bristolmyers  am may    investors business daily recovering biotech stock enters buy zone earns rating upgrade  am may    investors business daily how ionis helped rival alnylam — but tanked itself — on a key trial  pm may    investors business daily k biospecifics technologies corp  pm march    edgar online  edg  q k top biotech may unveil breakthrough treatment — and breakout move  am march    investors business daily celgene positions itself to take advantage of cancer medication  pm dec    investors business daily insiderinsightscom daily round up  bsm enzn tcon  am nov    seeking alpha will biospecifics technologies bstc continue to surge higher  pm nov    zackscom biospecifics technologies bstc management on q  results  earnings call transcript  pm nov    seeking alpha q biospecifics technologies corp  pm nov    edgar online  edg  q k hottest manufacturing stocks now – eglt lxu efoi sim  pm oct    investorplacecom parexel international prxl set to acquire execupharm  am sept    zackscom can the uptrend continue for biospecifics technologies bstc  am sept    zackscom hottest manufacturing stocks now – epzm fit dmpi crbp  pm sept    investorplacecom foamix pharmaceuticals fomx jumps stock rises   am sept    zackscom karyopharm reports positive multiple myeloma study data  am sept    zackscom sage therapeutics breakthrough status for depression drug  am sept    zackscom loading more headlines at a glance biospecifics technologies corp  wilbur street lynbrook new york  phone   industry biotechnology sector health carelife sciences fiscal yearend  view sec filings revenue m net income m  sales growth  employees  annual report for bstc newspressreleasecompanyusbstc press releases on bstc biospecifics technologies corp to present at the jefferies  healthcare conference  pm june    pr newswire  prf biospecifics technologies corp reports first quarter  financial results  pm may    pr newswire  prf biospecifics technologies corp initiates phase  clinical trial of xiaflex for treatment of uterine fibroids  am april    pr newswire  prf biospecifics technologies corp to present at the th annual needham healthcare conference  pm march    pr newswire  prf biospecifics technologies corp reports fourth quarter and full year  financial results  am march    pr newswire  prf biospecifics technologies corp to present at noblecon  noble capital markets thirteenth annual investor conference  pm jan    pr newswire  prf the life sciences report announces  companies selected for the  smallcap biotech watchlist  am jan    marketwired biospecifics technologies corp announces positive data from phase b study of cch in patients with cellulite  pm nov    pr newswire  prf biospecifics technologies corp reports third quarter  financial results  pm nov    pr newswire  prf biospecifics technologies corp to present at stifel  healthcare conference  am nov    pr newswire  prf biospecifics technologies corp to report third quarter  financial results on wednesday november    am nov    pr newswire  prf biospecifics technologies corp to present at two upcoming september conferences  am sept    pr newswire  prf biospecifics technologies corp to present at two upcoming september conferences  am sept    pr newswire  prf biospecifics technologies corp reports second quarter  financial results  pm aug    pr newswire  prf biospecifics technologies corp to report second quarter  financial results on tuesday august    am aug    pr newswire  prf trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  am edt july   marketstatecountryus new york open marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest aoil climbs to a nearly month high as us crude stockpiles drop a fourth week a cheap growth stocks for any market ahere’s how just  more home construction could ease the housing supply crunch apultegroup stock price target raised to  from  at mkm partners aif the stock market can make you rich why are so many americans poor athe allure of ‘damaged’ stocks as tech mania goes wild awithout irony walmart offers ideas to boost us manufacturing sector aboeing shares soar to record after ‘close to perfect’ earnings report afed to stick to plans for rate hike balancesheet selloff this year awhen should you make ‘course corrections’ to your retirement plan astock market drives to records after strong earnings abreakingboeings record stock rally adds  points to dow anewhome sales tread water miss wall street estimates a jobs where workers are most likely to have diabetes aoil nears twomonth high as eia reports a drop in us crude supplies for fourth week in a row agold slides for a third day in leadup to fed policy update awhat republican health proposals remain after one vote failed  ousting mueller would be inappropriate poll ait was a recordsetting week for people trying to take guns on planes aus distillate stockpiles down  million barrels eia asept wti crude trades at bbl on nymex up from  before supply data loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  biospecifics technologies corp to present at the jefferies  healthcare conference  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street biospecifics technologies corp to present at the jefferies  healthcare conference pr newswire jun    pm edt lynbrook ny june   prnewswire  biospecifics technologies corp nasdaq bstc a biopharmaceutical company that originated and continues to develop collagenase basedtherapies with a first in class collagenasebased product marketed as xiaflex ® in the us and xiapex ® in europe today announced that management will present a corporate overview at the upcoming jefferies  healthcare conference on friday june   at  pm et in new york ny a live webcast of the presentation can be accessed under events and presentation in the investors section of the companys website at wwwbiospecificscom or at httpwswcomwebcastjeffbstc about biospecifics technologies corp biospecifics technologies corp is a biopharmaceutical company that has developed injectable collagenase for thirteen clinical indications to date injectable collagenase is marketed as xiaflex ® in the us for the treatment of dupuytrens contracture and peyronies disease by biospecifics partner endo international plc endo xiaflex ® is also commercialized in japan europe canada and australia for dupuytrens contracture and for peyronies disease in europe and australia endo is partnered with sobi actelion and asahi kasei for dupuytrens contracture and peyronies disease outside the us the xiaflex research and development pipeline includes several additional promising indications biospecifics is managing the development of xiaflex for uterine fibroids and is conducting a phase  clinical trial for more information please visit  wwwbiospecificscom to view the original version on pr newswire visit httpwwwprnewswirecomnewsreleasesbiospecificstechnologiescorptopresentatthejefferieshealthcareconferencehtml source biospecifics technologies corp if you liked this article you might like biotechs among  stocks setting up for major breakouts heres how to rake in the profits off some potential big breakouts roberto pedone mar    pm edt  stocks making big moves on unusual volume these stocks rising on unusual volume are within range of triggering breakout trades roberto pedone mar    am edt  stocks breaking out on big volume heres how to trade seven stocks rising on largerthanaverage volume roberto pedone mar    am edt insider trading alert  uscr bstc and ocn traded by insiders stocks with insider trader activity include uscr bstc and ocn thestreet wire nov    am est trending facebooks q results should make snap ceo evan spiegel wish he had accepted a b buyout offer amazon with inflated discount rates we found  products youll want to check out jim cramer reveals why hes pleased with advanced micro devices and boeings earnings advanced micro devices could explode another  within hours chart boeing drives dow to new records sp  and nasdaq reach intraday highs advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers intellectual property originators in the development of injectable collagenase homeabout biospecificsbiospecifics overviewleadershippartnershipsour technologycollagen and scar tissuecollagenasetherapeutic useintellectual propertypipelinepipelinedupuytrens contracturepeyronies diseaseadhesive capsulitislipomacelluliteuterine fibroidsadditional indicationsinvestorsstock informationstock quoteinteractive chartir snapshothistorical stock priceinvestment calculatoranalyst coveragefinancial reportingsec filingsfundamentalsir key ratiosannual reportscorporate governancepress releasesevents and presentationfaqsemail alertsget news alerts by emailall rss feedscontact uscontactcontact us via email intellectual property in this section collagen and scar tissuecollagenasetherapeutic useintellectual property view the biospecifics  corporate presentation   we have strong longterm patent protection for injectable collagenase biospecifics owns coowns or controls patents and patent applications for injectable collagenase to treat dupuytrens contracture peyronies disease frozen shoulder syndrome removal of adipose tissue others   longterm patent protection for cch dupuytrens contracture   biologic exclusivity until  drug product composition patent until  peyronies disease orphan drug protection in us until  drug product composition patent until  patents and patent applications owned coowned or controlled by biospecifics for injectable collagenase to treat dupuytrens contracture peyronies disease removal of adipose tissue and frozen shoulder syndrome and others royalties through  the company also has additional patents pending and intends to seek patent protection whenever available for any products or product candidates and related technology the company develops or acquires in the future     copyright   biospecifics technologies corp  all rights reserved sitemapcontact ussearch biospecifics technologies corp announces initiation of phase ii trial for canine lipomas         homenewsfilexbrlprintingabout newsfilecareerscontactfrançais     biospecifics technologies corp announces initiation of phase ii trial for canine lipomas lynbrook new yorknewsfile corp  may    biospecifics technologies corp nasdaq bstc a biopharmaceutical company developing first in class collagenasebased products marketed as xiaflex® in the us and xiapex® in europe and eurasia today announced that it has initiated a placebo controlled randomized phase ii clinical trial chien to evaluate the efficacy of xiaflex collagenase clostridium histolyticum for canines with benign subcutaneous lipomas canine lipomas are encapsulated fat deposits that occur under the skin and affect  million dogs in the us biospecifics anticipates that it will complete this study in the first half  “we are happy to report the initiation of chien as we believe there is strong potential for injectable collagenase in the treatment of lipomas in canines and a high interest among veterinarians in the product to treat this condition” said thomas wegman president of biospecifics “canine lipomas represent a large market opportunity with  million potential injections in the us annually in addition we look forward to the initiation of our phase ii dose escalation clinical trial of xiaflex for human lipomas shortly”this single injection study will evaluate  dogs randomized  xiaflex to placebo the lipoma volume will be measured at baseline  month and  monthsthe primary efficacy endpoint is the relative change from baseline for lipoma volume at the  month visit as determined by ct scan the secondary efficacy endpoints include an analysis of responders at  month and  months a responder is defined as a canine with a ≥ decrease in the volume of the lipoma under study relative to baseline as measured by ct scan the additional secondary efficacy endpoints are the relative change from baseline for lipoma volume at the  month visit as determined by ct scan relative change from baseline for lipoma surface area at the  month and  month visits as determined by caliper measurements lipoma texture and hardness and dog owner satisfaction as determined from a questionnaire the study is being conducted at the california veterinary specialists carlsbad hospital and is being led by investigator sarit dhupa dvm bvsc dr dhupa is a diplomate of the american college of veterinary surgeons california veterinary specialists is one of the nation’s leading providers of advanced veterinary services for animals in need of critical emergency care and treatment of serious acute and chronic illnessesbiospecifics’ partner auxilium pharmaceuticals inc auxilium has the option to license development and marketing rights to this indication which would trigger an optin payment and potential future milestone payments from auxilium to biospecificsabout chien clinical trialprior to the initiation of chien biospecifics conducted the chien trial which was an open label trial designed to evaluate the efficacy of injectable collagenase in canine lipoma in healthy dogs with subcutaneous lipomas inclusion criteria required the lipoma to be benign superficial and easily measureable all dogs had a second lipoma that was untreated and used as a control at  months postinjection the lipoma size in the three evaluable dogs was reduced to   or  of the original size as measured by a ct scan by contrast the untreated lipomas were   and  of the original size at day  thus the treated lipomas showed on average a  reduction in the size of the lipoma versus an increase on average in the size of the untreated controls of about canine lipomaslipomas are encapsulated fat deposits that occur under the skin lipomas restrict motion in older dogs and surgical excision of the lipoma is the only proven therapy surgical excision requires the use of general anesthesia and it has been estimated that up to  of sick dogs die as a complication of general anesthesia lipomas occur in  of the dog population or in approximately  million dogs in the usabout biospecifics technologies corp biospecifics technologies corp is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications today injectable collagenase registered as xiaflex® is marketed in the us for the treatment of dupuytrens contracture in adults with a palpable cord by the company’s partner auxilium pharmaceuticals inc auxilium and is marketed in europe under the trademark xiapex® by pfizer ltd pfizer xiaflex will be tested in the clinic for six promising indications during  auxilium is developing xiaflex for the treatment of peyronies disease which is currently in phase iii pivotal clinical trials as well as for frozen shoulder adhesive capsulitis and cellulite which are in phase ii and phase i respectively auxilium is also conducting a phase iiib trial of xiaflex for dupuytrens contracture patients with multiple palpable cords biospecifics is developing xiaflex for human and canine lipomas pfizer has development and commercialization rights for xiapex for dupuytrens contracture and peyronies disease in the  european union member countries and  other european and eurasian countries asahi kasei pharma corporation has development and commercialization rights for xiaflex for the same two indications in japan and actelion pharmaceuticals has development and commercialization rights for xiaflex for these two indications in canada australia brazil and mexico more information about the company may be found on its website at wwwbiospecificscomforward looking statements this release includes “forwardlooking statements” within the meaning of and made pursuant to the safe harbor provisions of the private securities litigation reform act of  all statements other than statements of historical fact are “forwardlooking statements” the forwardlooking statements include statements concerning among other things the potential market for xiaflex in canine lipomas the timing for completing the clinical trial in canine lipomas and the outcome of that clinical trial the initiation of a phase ii dose escalation clinical trial of xiaflex for human lipomas and the promise of xiaflex as a treatment for particular indications in some cases these statements can be identified by forwardlooking words such as “believe” “expect” “anticipate” “plan” “estimate” “likely” “may” “will” “could” “continue” “project” “predict” “goal” the negative or plural of these words and other similar expressions these forwardlooking statements are predictions based on biospecifics’ current expectations and its projections about future events there are a number of important factors that could cause biospecifics’ actual results to differ materially from those indicated by such forwardlooking statements including the ability of biospecifics’ partner auxilium and its partners pfizer inc asahi kasei pharma corporation and actelion pharmaceuticals ltd to achieve their objectives for xiaflex in their applicable territories the success of the phase iii trials for xiaflex for the treatment of peyronie’s disease the market for xiaflex in and initiation and outcome of clinical trials for additional indications including frozen shoulder cellulite human lipoma and canine lipoma all of which will determine the amount of milestone royalty and sublicense income biospecifics may receive the potential of xiaflex to be used in additional indications the timing of results of any clinical trials the timing of regulatory filings and action the receipt of any applicable milestone payments from auxilium whether royalty payments biospecifics is entitled to receive will exceed setoffs and other risk factors identified in biospecifics’ annual report on form k for the year ended december   and its current reports on form k filed with the securities and exchange commission all forwardlooking statements included in this release are made as of the date hereof and biospecifics assumes no obligation to update these forwardlooking statements contact biospecifics technologies corp thomas l wegman president   thomaswegmanbiospecificscom brodbelt vet j  dec    lund javma vol  no  may   us pet ownership  demographics sourcebook  edition follow newsfilecorp the markets dailythemarketsdaily  jul analysts set  target price for biospecifics technologies corp bstc httpstcojuyffvusp valuetradesstocktradepicks  jul must read new weed deal will make this stock run huge httpstcoaqshumri pwer mrcc dtlk spff taoif cuz bstc pndzf emf snda companys news releases biospecifics technologies corp reports fourth quarter and full year  financial resultsbiospecifics technologies corp announces online publication in the journal of urology of results from the impress trials of xiaflexr in peyronies diseasebiospecifics technologies corp reports second quarter  financial resultsbiospecifics technologies corp reports first quarter  financial resultsbiospecifics technologies corp announces initiation of phase ii trial for canine lipomas visit companys profile page copyright  newsfile corp all rights reserved terms and conditions of use  privacy policy  antispam policy  contact us biospecifics technologies corp initiates phase  clinical trial of xiaflex for treatment of uterine fibroids  apr   originators in the development of injectable collagenase press releases in this section welcome stock information financial reporting corporate governance press releases events and presentation faqs email alerts contact us stock quotenasdaqbstc dymomoyryr biospecifics technologies corp initiates phase  clinical trial of xiaflex for treatment of uterine fibroids apr   lynbrook ny april   prnewswire  biospecifics technologies corp nasdaq bstc a biopharmaceutical company that originated and continues to develop collagenase basedtherapies with a first in class collagenasebased product marketed as xiaflex® in the us and xiapex® in europe today announced that it has initiated an openlabel dose escalation phase  clinical trial of xiaflex for the treatment of uterine fibroids the treatment of our first patient in this trial for uterine fibroids is an important milestone for biospecifics and supports our business objective to develop xiaflex for medically necessary indications commented thomas l wegman president of biospecifics we believe there are strong benefits to xiaflex as a potential nonsurgical treatment for uterine fibroid patients and that achieving a reduction in the size and stiffness of the fibroids will decrease symptoms of pain and bleeding avoid the need for surgical procedures and result in a better quality of life for affected women the phase  openlabel dose escalation study is being conducted at the department of gynecology  obstetrics at johns hopkins university and will enroll  female subjects treated prior to hysterectomy three subjects have been injected with saline only to evaluate the safety and effectiveness of the injection method and the remaining  subjects will now be injected with increasing doses of xiaflex the primary endpoint will assess the safety and tolerability of a single injection of xiaflex directly into the uterine fibroids at three doses under transvaginal ultrasound guidance the secondary endpoints will assess symptoms of pain and bleeding quality of life throughout the study shrinkage of xiaflex treated fibroids in size increased rates of apoptosis in treated fibroids and a decrease in the collagen content of treated fibroids about uterine fibroids uterine fibroids are very common benign tumors in the reproductive tract that contain large amounts of collagen which may cause pelvic discomfort and pain decreased fertility pregnancy complications an increased rate of miscarriage uterine bleeding prolonged menstrual bleeding and frequent urination uterine fibroids are the leading cause of hysterectomies in the us accounting for about  hysterectomies and  myomectomies performed each year uterine fibroids have been estimated to cost up to  billion annually in direct costs in the us and there is a high level of recurrence with current treatment options about biospecifics technologies corp biospecifics technologies corp is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date injectable collagenase is marketed as xiaflex® in the us for the treatment of dupuytrens contracture and peyronies disease by biospecifics partner endo international plc endo xiaflex® is also commercialized in japan europe canada and australia for dupuytrens contracture and for peyronies disease in europe and australia endo is partnered with sobi actelion and asahi kasei for dupuytrens contracture and peyronies disease outside the us the xiaflex research and development pipeline includes several additional promising indications biospecifics is managing the development of xiaflex for uterine fibroids and is conducting a phase  clinical trial for more information please visit wwwbiospecificscom forwardlooking statements this press release includes forwardlooking statements within the meaning of and made pursuant to the safe harbor provisions of the private securities litigation reform act of  all statements other than statements of historical fact including statements regarding the companys strategy future operations future financial position future revenues projected costs prospects plans and objectives of management expected revenue growth and the assumptions underlying or relating to such statements are forwardlooking statements the forwardlooking statements in this press release include statements concerning among other things whether there are strong benefits to xiaflex as a potential nonsurgical treatment for uterine fibroid patients and whether achieving a reduction in the size and stiffness of the fibroids will decrease symptoms of pain and bleeding avoid the need for surgical procedures and result in a better quality of life for affected women in some cases these statements can be identified by forwardlooking words such as believe expect plan may will can and could the negative or plural of these words and other similar expressions these forwardlooking statements are predictions based on biospecifics current expectations and its projections about future events and various assumptions there can be no assurance that biospecifics will realize its expectations or that biospecifics beliefs will prove correct there are a number of important factors that could cause biospecifics actual results to differ materially from those indicated by such forwardlooking statements including the timing of regulatory filings and action the ability of endo and its partners asahi kasei pharma corporation actelion ltd and swedish orphan biovitrum ab to achieve their objectives for xiaflex in their applicable territories the market for xiaflex in and timing initiation and outcome of clinical trials for additional indications that will determine the amount of milestone royalty markup on cost of goods sold license and sublicense income biospecifics may receive the potential of xiaflex to be used in additional indications endo modifying its objectives or allocating resources other than to xiaflex and other risk factors identified in biospecifics annual report on form k for the year ended december   and its current reports on form k filed with the securities and exchange commission all forwardlooking statements included in this press release are made as of the date hereof are expressly qualified in their entirety by the cautionary statements included in this press release and except as may be required by law biospecifics assumes no obligation to update these forwardlooking statements source biospecifics technologies corpfor further information biospecifics technologies corp thomas l wegman president   thomaswegmanbiospecificscom   copyright   biospecifics technologies corp  all rights reserved sitemap contact us search biospecifics technologies corp to present at the jefferies  healthcare conference biospecifics technologies corp to present at the jefferies  healthcare conference news provided by biospecifics technologies corp jun    et share this article lynbrook ny june   prnewswire  biospecifics technologies corp nasdaq bstc a biopharmaceutical company that originated and continues to develop collagenase basedtherapies with a first in class collagenasebased product marketed as xiaflex® in the us and xiapex® in europe today announced that management will present a corporate overview at the upcoming jefferies  healthcare conference on friday june   at  pm et in new york ny a live webcast of the presentation can be accessed under events and presentation in the investors section of the companys website at wwwbiospecificscom or at httpwswcomwebcastjeffbstc about biospecifics technologies corp biospecifics technologies corp is a biopharmaceutical company that has developed injectable collagenase for thirteen clinical indications to date injectable collagenase is marketed as xiaflex® in the us for the treatment of dupuytrens contracture and peyronies disease by biospecifics partner endo international plc endo xiaflex® is also commercialized in japan europe canada and australia for dupuytrens contracture and for peyronies disease in europe and australia endo is partnered with sobi actelion and asahi kasei for dupuytrens contracture and peyronies disease outside the us the xiaflex research and development pipeline includes several additional promising indications biospecifics is managing the development of xiaflex for uterine fibroids and is conducting a phase  clinical trial for more information please visit wwwbiospecificscom to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesbiospecificstechnologiescorptopresentatthejefferieshealthcareconferencehtml source biospecifics technologies corp related links httpwwwbiospecificscom may    et preview biospecifics technologies corp reports first quarter  financial results my news release contains wide tables view fullscreen also from this source may    et biospecifics technologies corp reports first quarter  apr    et biospecifics technologies corp initiates phase  clinical trial explore more news releases in similar topics biotechnology health care  hospitals medical pharmaceuticals pharmaceuticals you just read biospecifics technologies corp to present at the jefferies  healthcare conference news provided by biospecifics technologies corp jun    et share this article looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft national pen® official site  promotional products since  pens  writing pens  writing pens plastic retractable metal stick translucent rollerball grip gel ink twist novelty stylus gift sets blue ink light up pens smoothwrite™ ink highlighters markers pencils standard mechanical golf pencils shop all pens  writing shop by family contour pens squiggle pens colorama pens cirrus pens dynagrip pens paragon pens shop by brand bic® paper mate goofy uniball sharpie featured item bering stylus pen as low as  shop now save on best selling products personalized gift ideas bags bags business bags laptop briefcases backpacks drawstring bags tote bags reusable shopping bags paper bags travel bags luggage accessories coolers  lunch bags duffle bags canvas bags plastic bags golf bags shop all bags shop by brand high sierra koozie® elleven case logic featured item budget shopper tote as low as  shop now save on best selling products personalized gift ideas drinkware drinkware travel mugs stadium cups glassware tumblers bottle openers thermos water bottles ceramic mugs beverage holders koozie® coasters shop all drinkware shop by brand tritan koozie® cool gear featured item square coaster with bottle opener as low as  shop now save on best selling products personalized gift ideas stationery stationery  calendars stationery sticky notes presentation folders padfolios note pads note pad sets flag sets document holders business card holders holiday cards calendars wall calendars stick up calendars magnetic calendars planners  diaries desk calendars calendar accessories featured item spiral bound notebook with colored dividers as low as  shop now save on best selling products personalized gift ideas tech  office tech  office tech gadgets usb flash drives stylus cell phone stands selfie sticks audio  music earbuds  headphones speakers portable chargers power banks tech accessories mouse pads desk accessories calculators letter opener rulers magnets auto magnets shaped magnets business card magnets business card products stress relief shop all tech  office shop by brand bic® ifidelity mycharge tangle zoom featured item gb promotional usb flash drive as low as  shop now save on best selling products personalized gift ideas tradeshow tradeshow lanyards  badges banners  signs candy table covers  throws tote bags buttons pins ribbons balloons accessories shop all tradeshow featured item  crystal balloon as low as  shop now save on best selling products personalized gift ideas auto  home auto  home home living clocks  watches piggy banks picture frames ornaments home accessories magnets apparel shirts polo shirts outerwear womens clothing mens clothing headwear sunglasses bracelets kitchenware kitchen products clips auto accessories ice scrapers flashlights outdoor umbrellas blankets sports outdoor accessories golf chairs beach balls wellness personal care lip balm hand sanitizers first aid emery boards tools screwdrivers carpenter tools tape measures knives keychains plastic metal light up shop all auto  home shop by brand gildan slazenger hanes carhartt cutter  buck titleist featured item led flashlight key chain as low as  shop now save on best selling products personalized gift ideas gifts gifts top gift ideas gift bags back to school food  drinkware reunion favors calendars  planners rush products tech gadgets luxury gifts wedding gifts graduation gifts shop all gifts featured item gelato pen and flashlight gift set as low as  shop now save on best selling products personalized gift ideas closeout closeout auto  home drinkware office tech gadgets writing see all closeout save on best selling products personalized gift ideas see all quick shopping links toggle links quick shopping links national pen brand buy  get some free sales  closeout new products best selling products rush service full color designs submit personalized pens retractable pens plastic pens metal pens gel ink pens blue ink pens bic  national pen bags tote bags coolers drinkware travel mugs water bottles office magnets letter openers auto  home key chains flashlights stationery note pads sticky notes calendars popular brands bic papermate uniball sharpie koozie xclose free shipping  setup for new customers with coupon code free popular searches contour pens squiggle pens colorama pens cirrus pens dynagrip pens paragon pens superball pen flashlight pens custom selfie stick key chain flashlight stylus pens bic pens tech gadgets budget friendly products low minimum pens all promotional products national pen®  your  source for promotional products and personalized pens national pen® offers high quality personalized products at factorydirect pricing in business over  years we manufacture and assemble many of our promotional products in the usa advertise your business by imprinting your company name or logo on personalized pens key chains note pads magnets calendars mugs tote bags  more personalized promotional products are perfect for trade show giveaways customer appreciation corporate events and marketing your brand close join our email list join our list to be the first to know about new products special offers sales and more plus get  off your next order email first name last name cancel you can opt out at anytime please refer to our privacy policy or contact us for more details xclose survey biospecifics technologies corp bstc  stock predictions  price targets facebook autocomplete demo post a rating  month price target   home trending sign up log in biospecifics technologies corp bstc median target price  positive ratings  latest  rodman  renshaw  buy     view all analyst ratings for bstc »